Patents by Inventor Steven Woodhead
Steven Woodhead has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240043428Abstract: The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.Type: ApplicationFiled: December 21, 2022Publication date: February 8, 2024Inventors: Gilbert BESONG, Christopher Thomas BRAIN, Clinton A. BROOKS, Miles Stuart CONGREVE, Claudio DAGOSTIN, Guo HE, Ying HOU, Steven HOWARD, Yue LI, Yipin LU, Paul MORTENSON, Troy SMITH, Moo Je SUNG, Steven WOODHEAD, Wojciech WRONA, Bharat LAGU
-
Publication number: 20210253578Abstract: The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.Type: ApplicationFiled: September 16, 2020Publication date: August 19, 2021Inventors: Gilbert BESONG, Christopher Thomas BRAIN, Clinton A. BROOKS, Miles Stuart CONGREVE, Claudio DAGOSTIN, Guo HE, Ying HOU, Steven HOWARD, Yue LI, Yipin LU, Paul MORTENSON, Troy SMITH, Moo Je SUNG, Steven WOODHEAD, Wojciech WRONA, Bharat LAGU
-
Publication number: 20180155351Abstract: The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.Type: ApplicationFiled: February 1, 2018Publication date: June 7, 2018Inventors: Gilbert Besong, Christopher Thomas Brain, Clinton A. Brooks, Miles Stuart Congreve, Claudio Dagostin, Guo He, Ying Hou, Steven Howard, Yue Li, Yipin Lu, Paul Mortenson, Troy Smith, Moo Je Sung, Steven Woodhead, Wojciech Wrona, Bharat Lagu
-
Publication number: 20170183352Abstract: The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.Type: ApplicationFiled: August 8, 2016Publication date: June 29, 2017Applicants: Novartis AG, Astex Therapeutics Ltd.Inventors: Gilbert BESONG, Christopher Thomas BRAIN, Clinton A. BROOKS, Miles Stuart CONGREVE, Claudio DAGOSTIN, Guo HE, Ying HOU, Steven HOWARD, Yue LI, Yipin LU, Paul MORTENSON, Troy SMITH, Moo Je SUNG, Steven WOODHEAD, Wojciech WRONA, Bharat LAGU
-
Patent number: 9416136Abstract: The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.Type: GrantFiled: January 17, 2014Date of Patent: August 16, 2016Assignees: Novartis AG, Astex Therapeutics, Ltd.Inventors: Gilbert Besong, Christopher Thomas Brain, Clinton A Brooks, Miles Stuart Congreve, Claudio Dagostin, Guo He, Ying Hou, Steven Howard, Yue Li, Yipin Lu, Paul Mortenson, Troy Smith, Moo Je Sung, Steven Woodhead, Wojciech Wrona, Bharat Lagu
-
Patent number: 9078017Abstract: The invention relates to a method and device for buffering data for multiplexing. The invention also relates to a method of multiplexing and to a multiplexer arrangement using the method and device for buffering data for multiplexing. In one embodiment the invention can be applied to the buffering of non-traffic data, such as firmware updates or other supplementary information, before multiplexing the non-traffic data with traffic data, such as television data of television channels, to form a satellite broadcast channel. In embodiments of the invention, non-traffic data for multiplexing is buffered and then read out again for multiplexing at a rate which is a function of buffer fullness. The non-traffic data may be multiplexed with at least one traffic data channel. A multiplexer can view the non-traffic data channel as another multiplexing input and can allocate the available bit rate between the traffic data channels and the non-traffic data accordingly.Type: GrantFiled: November 26, 2010Date of Patent: July 7, 2015Assignee: Telefonaktiebolaget L M Ericsson (publ)Inventors: Jeremy Bennett, Steven Woodhead
-
Publication number: 20140135312Abstract: The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.Type: ApplicationFiled: January 17, 2014Publication date: May 15, 2014Applicants: Astex Therapeutics Ltd., Novartis AGInventors: Gilbert BESONG, Christopher Thomas Brain, Clinton A. Brooks, Miles Stuart Congreve, Claudio Dagostin, Guo He, Ying Huo, Steven Howard, Yue Ll, Yipin Lu, Paul Mortenston, Troy Smith, Moo Je Sung, Steven Woodhead, Wojciech Wrona, Bharat Lagu
-
Publication number: 20130247126Abstract: The invention relates to a method and device for buffering data for multiplexing. The invention also relates to a method of multiplexing and to a multiplexer arrangement using the method and device for buffering data for multiplexing. In one embodiment the invention can be applied to the buffering of non-traffic data, such as firmware updates or other supplementary information, before multiplexing the non-traffic data with traffic data, such as television data of television channels, to form a satellite broadcast channel. In embodiments of the invention, non-traffic data for multiplexing is buffered and then read out again for multiplexing at a rate which is a function of buffer fullness. The non-traffic data may be multiplexed with at least one traffic data channel. A multiplexer can view the non-traffic data channel as another multiplexing input and can allocate the available bit rate between the traffic data channels and the non-traffic data accordingly.Type: ApplicationFiled: November 26, 2010Publication date: September 19, 2013Applicant: TELEFONAKTIEBOLAGET L M ERICSSON (PUBL)Inventors: Jeremy Bennett, Steven Woodhead
-
Publication number: 20110152244Abstract: The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.Type: ApplicationFiled: August 20, 2009Publication date: June 23, 2011Applicants: NOVARTIS AG, ASTEX THERAPEUTICS LTD.Inventors: Gilbert Besong, Christopher Thomas Brain, Clinton A. Brooks, Miles Stuart Congreve, Claudio Dagostin, Guo He, Ying Huo, Steven Howard, Yue Li, Yipin Lu, Paul Morteson, Troy Smith, Moo Sung, Steven Woodhead, Wojciech Wrona
-
Publication number: 20100105653Abstract: The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.Type: ApplicationFiled: August 21, 2009Publication date: April 29, 2010Inventors: Gilbert Besong, Christopher Thomas Brain, Clinton A. Brooks, Miles Stuart Congreve, Claudio Dagostin, Guo He, Ying Huo, Steven Howard, Yue Li, Yipin Lu, Paul Mortenson, Troy Smith, Moo Je Sung, Steven Woodhead, Wojciech Wrona
-
Publication number: 20070082898Abstract: The invention provides the use of a compound for the manufacture of a medicament for the prophylaxis or treatment of a disease state or condition mediated by a p38 MAP kinase; the compound being defined by formula (I): wherein: R1 and R2 are the same or different and each is selected from hydrogen, C1-4 hydrocarbyl, halogen and cyano; X is selected from C?O, C?S, C(?O)NH, C(?S)NH, C(?O)O, C(?O)S, C(?S)O and C(?S)S; R3 is selected from aryl and hetcroaryl groups each having from 5 to 12 ring members, the aryl and heteroaryl groups each being unsubstituted or substituted by one or more substituent groups R7 selected from halogen, hydroxy, trifluoromethyl, cyano, nitro, carboxy, amino, carbocyclic and heterocyclic groups having from 3 to 12 ring members; a group Ra—Rb wherein Ra is a bond, 0, CO, X1C(X2), C(X2)X1, X1C(X2)X1, S, SO, SO2, NRc, SO2NRc or NRcSO2; and Rb is selected from hydrogen, carbocyclic and heterocyclic groups having from 3 to 7 ring members, and a C1-8 hydrocarbyl group optionally substitutedType: ApplicationFiled: April 13, 2004Publication date: April 12, 2007Applicant: Astex Therapeutics LimitedInventors: Adrian Gill, Steven Woodhead, Maria Carr
-
Publication number: 20060063782Abstract: Compounds of the formula (I), wherein: —X?Y— is selected from —CR<2>=CR<3>— and —CR<2>?N—; R<1> is selected from H, halo, NRR?, NHC(?O)R, NHC(?O)NRR?, NH2SO2R, and C(?O)NRR?; R<2> and R<3> (where present) are independently selected from H, optionally substituted C1-7 alkyl, optionally substituted C5-20 aryl, optionally substituted C3-20 heterocyclyl, halo, amino, amido, hydroxy, ether, thio, thioether, acylamido, ureido and sulfonamino; R<4> is an optionally substituted C5-20 aryl or C5-20 heteroaryl group; and R<5> is selected from R<5?>, halo, NHR<5?>, C(?O)NHR<5?>, OR<5?>, SR<5?>, NHC(?O)R<5?>, NHC(?O)NHR<5?>, NHS(?O)R<5?>, wherein R<5?> is H or C1-3 alkyl (optionally substituted by halo, NH2, OH, SH) are disclosed for use in therapy and for treating diseases ameliorated by inhibiting p38 MAP kinase.Type: ApplicationFiled: July 3, 2003Publication date: March 23, 2006Inventors: Christopher Murray, Michael Hartshorn, Martyn Frederickson, Miles Congreve, Alessandro Padova, Steven Woodhead, Adrian Gill, Andrew Woodhead